Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1995-4-20
pubmed:abstractText
We examined the effects of TCV-116, a non-peptide selective AT1 receptor antagonist, on cellular phenotype and on the expression of the transforming growth factor-beta 1 (TGF-beta 1) and extracellular matrix genes in the kidneys of stroke-prone spontaneously hypertensive rats (SHRSP). SHRSP were given vehicle or TCV-116 (10 mg/kg/day) by gastric gavage for 10 weeks (from the age of 22 to 32 weeks). Renal mRNA levels were measured by Northern blot analysis. In vehicle-treated 32-week-old SHRSP, urinary albumin excretion per 24 h was about 26-fold greater than that in age-matched Wistar-Kyoto (WKY) rats, and the mRNA levels of renal TGF-beta 1, fibronectin and collagen types I and III in SHRSP were all several-fold higher than those in WKY. Immunohistochemical studies showed the prominent presence of alpha-smooth muscle actin-expressing glomerular cells in SHRSP, in contrast to their absence in WKY. Treatment of SHRSP with TCV-116 decreased urinary albumin excretion and renal mRNA levels for TGF-beta 1 and for the above-mentioned extracellular matrix components. TCV-116 prevented the phenotypic modulation of glomerular cells in SHRSP. These results suggest that AT1 receptor antagonists may have powerful renal protective effects.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0803-8023
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
54-6
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:7889201-Albuminuria, pubmed-meshheading:7889201-Angiotensin II, pubmed-meshheading:7889201-Angiotensin Receptor Antagonists, pubmed-meshheading:7889201-Animals, pubmed-meshheading:7889201-Antihypertensive Agents, pubmed-meshheading:7889201-Benzimidazoles, pubmed-meshheading:7889201-Biphenyl Compounds, pubmed-meshheading:7889201-Cerebrovascular Disorders, pubmed-meshheading:7889201-Extracellular Matrix, pubmed-meshheading:7889201-Gene Expression, pubmed-meshheading:7889201-Hypertension, Renal, pubmed-meshheading:7889201-Kidney, pubmed-meshheading:7889201-Kidney Glomerulus, pubmed-meshheading:7889201-Male, pubmed-meshheading:7889201-Phenotype, pubmed-meshheading:7889201-Prodrugs, pubmed-meshheading:7889201-RNA, Messenger, pubmed-meshheading:7889201-Rats, pubmed-meshheading:7889201-Rats, Inbred SHR, pubmed-meshheading:7889201-Rats, Inbred WKY, pubmed-meshheading:7889201-Receptors, Angiotensin, pubmed-meshheading:7889201-Sclerosis, pubmed-meshheading:7889201-Tetrazoles, pubmed-meshheading:7889201-Transforming Growth Factor beta
pubmed:year
1994
pubmed:articleTitle
Renal protective effect of TCV-116 in stroke-prone spontaneously hypertensive rats.
pubmed:affiliation
Department of Pharmacology, Osaka City University Medical School, Japan.
pubmed:publicationType
Journal Article